Metastatic Breast Cancer
Conditions
Keywords
Metastatic Breast Cancer, Pyrotinib Maleate, HER2 Targeted Therapy
Brief summary
To explore the efficacy and safety of pyrotinib combined with docetaxel regimen in the first-line treatment of HER2-positive metastatic breast cancer.
Detailed description
A multi-center, one-arm, open label design study,which is planned to enroll 79 patients with HER2-positive metastatic breast cancer receiving first-line treatment with pyrotinib and docetaxel. The main purpose of this study was to observe the efficacy and safety of first-line treatment with pyrrolidine and docetaxel for HER2-positive metastatic breast cancer.
Interventions
DRUGPyrotinib Maleate combine with Docetaxel
Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Pyrotinib Maleate combine with Docetaxel
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed histologically. * HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline). * do not chemotherapy for recurrent and metastatic lesions, but local treatment for local symptoms, such as radiotherapy for relieving bone pain, is allowed. * if the patient is bilateral breast cancer, metastasis lesions must be HER2-positive. * 18-70 years old. * ECOG PS 0～1. * life expectancy is not less than 12 weeks. * at least one measurable lesion according to RECIST 1.1. * Endocrine therapy is allowed to relapse/metastasis disease; patients with previous adjuvant/neoadjuvant use of Taxus and trastuzumab, disease-free interval from the end of last adjuvant/neoadjuvant Taxus therapy to the progression of tumors (≥12 months), and disease-free interval from the end of last adjuvant/neoadjuvant trastuzumab to the progression of tumors (≥ 6 months). * ANC ≥ 1.5×109/L,PLT ≥ 75×109/L,Hb ≥ 100 g/L;TBIL≤1.0ULN；ALT and AST≤3×ULN（ALT and AST≤5×ULN if liver metastasis）;BUN and Cr≤1.5×ULN and CCr≥50 mL/min. * LVEF ≥ 50% and QTc≤480 ms. * known hormone receptor status. * Signed informed
Exclusion criteria
* Central nervous system metastasis. * Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption. * patient who received radiotherapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks before admission; those who received anti-tumor endocrine therapy after screening period * Participated in other drug clinical trials within 4 weeks before admission * Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have been used or are being used in the past. * Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years. * Receive other antitumour treatment at the same time * A history of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired, congenital immunodeficiency disorders, or organ transplantation, is known. * Has suffered from any heart disease * Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial * According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.). * The patient did not recover from the toxicity of previous treatment to grade 0-1 (except hair loss). * History of neurological or psychiatric disorders * Along with CYP3A4 inhibitors or inducers or drugs that are using to prolong the QT interval * Researchers believe that patients are not suitable for any other situation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | from enrollment to progression or death (for any reason), assessed up to 100 months | Ratio of CR and PR in all subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | from enrollment to progression or death (for any reason),assessed up to 100 months | Progression-Free Survival |
| DoR | The first evaluation of CR or PR to progression or death (for any reason),assessed up to 100 months | Duration of Response |
| Clinical Benefit Rate | from enrollment to progression or death (for any reason),assessed up to 100 months | Ratio of CR,PR and SD greater than or equal to 24 weeks in all subjects |
| OS | from enrollment to death (for any reason).assessed up to 100 months | Overall Survival |
Other
| Measure | Time frame | Description |
|---|---|---|
| adverse event | from enrollment to 30 days after the last dose administrate | Adverse events are described in terms of CTC AE 5.0 |
Countries
China
Contacts
Primary ContactXiaojia Wang, PhD
Backup ContactJian Huang, chief doctor
Outcome results
None listed